Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors
Transplant Infectious Disease · 2026-07 · 28 (4)
DOI: 10.1111/tid.70202 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Transplant Infectious Disease, online erschienen am 13.03.2026. Verfasst von Christine E Koval und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Tissue Donors, Graft Rejection, SARS-CoV-2. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Data demonstrates safety and short‐term success of kidney transplantation (KT) from SARS‐CoV‐2 NAT‐positive organ donors (NAT+) compared to NAT‐negative donors. However, detailed reports of longer‐term graft outcomes are limited and lack granular data on donor SARS‐CoV‐2 infection severity.
Methods
We retrospectively reviewed records from 220 recipients of KT (KTRs) at our institution from February 1, 2021, to January 31, 2022. We compared 1‐ and 3‐year allograft‐specific outcomes for KTRs from NAT+ ( N = 59), CoV‐COD (COVID as cause of death) ( N = 56), and NAT‐neg ( N = 105) donors. We reviewed and compared pathology findings for allograft biopsies for all groups up to 1 year. We examined the association of eGFR at 3 years with CoV‐donor status using multivariable linear regression.
Results
At 1 year, there was no difference in rejection or kidney pathologies by CoV‐donor status. At 3 years, there was no difference in patient death or graft loss by group. For subjects without graft loss, eGFR at 3 years for NAT+, CoV‐COD, and NAT‐neg donors was 54.8 (21.8), 45.6(17.9), and 48.4 (23.3) mL/min/m 2 , respectively ( p = 0.61). On multivariable analysis, there was no significant association of eGFR with CoV‐donor status.
Conclusions
We found no significant difference in pathological findings or 3‐year allograft outcomes following KT from NAT‐negative, NAT+, or CoV‐COD donors. Despite modestly reduced eGFR for COV‐COD on unadjusted analysis, kidneys from donors with a spectrum of COVID severities did not experience significantly poorer allograft outcomes over 3 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Pathology, Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Kidney Medicine, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Christine E Koval, Mohamed Eltemamy, Nabin K Shrestha, Leal Herlitz, Emilio D Poggio, Alvin C Wee
Zitieren
APA
Koval, C. E., Eltemamy, M., Shrestha, N. K., Herlitz, L., Poggio, E. D., & Wee, A. C. (2026). Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors. Transplant Infectious Disease, 28(4). https://doi.org/10.1111/tid.70202
Vancouver
Koval CE, Eltemamy M, Shrestha NK, Herlitz L, Poggio ED, Wee AC. Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors. Transplant Infectious Disease. 2026;28(4). doi:10.1111/tid.70202
BibTeX
@article{Koval2026,
author = {Koval, Christine E and Eltemamy, Mohamed and Shrestha, Nabin K and Herlitz, Leal and Poggio, Emilio D and Wee, Alvin C},
title = {Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors},
journal = {Transplant Infectious Disease},
year = {2026},
volume = {28},
number = {4},
doi = {10.1111/tid.70202}
}
EUVIMED